Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE®, or Staccato loxapine, and our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.24 |
| Quarterly EPS Est: | -0.5 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1.67 |
Data is provided by Zacks Investment Research

